| Target Price | $117.30 |
| Price | $110.47 |
| Potential |
6.18%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2026 .
The average Rhythm Pharmaceuticals, Inc. target price is $117.30.
This is
6.18%
register free of charge
$164.85
49.23%
register free of charge
$95.95
13.14%
register free of charge
|
|
| A rating was issued by 20 analysts: 19 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2026 of
6.18%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 130.13 | 190.16 |
| 68.06% | 46.13% | |
| EBITDA Margin | -202.83% | -94.14% |
| 13.99% | 53.59% | |
| Net Margin | -203.31% | -103.21% |
| 14.76% | 49.24% |
16 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2025 . The average Rhythm Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Rhythm Pharmaceuticals, Inc. EBITDA forecast 2025. The average Rhythm Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Rhythm Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.34 | -3.07 |
| 35.63% | 29.26% | |
| P/E | negative | |
| EV/Sales | 37.63 |
16 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Rhythm Pharmaceuticals, Inc....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 29 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 29 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Sep 25 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 25 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 24 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


